Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Chief Financial Officer | January 23, 2024 | January 25, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MADRIGAL PHARMACEUTICALS, INC.
Report date January 23, 2024 · Filed January 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,737 |
Reported balance
After 2024-01-23 transaction · row 1
1 source rowRow 1 · 2024-01-23 · Grant · Acquired 4,803 · Balance 18,737 F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 23, 2025, January 23, 2026, January 23, 2027 and January 23, 2028, provided the Reporting Person continues in service with the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $229.00 · Expires 2031-01-23 | Direct | 7,238 |
Reported balance
After 2024-01-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-23 · Grant · Acquired 7,238 · Balance 7,238 F2: The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. |
| Market Stock UnitSEC Table II · derivative / convertible security | Direct | 4,803 |
Reported balance
After 2024-01-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-23 · Grant · Acquired 4,803 · Balance 4,803 F3: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 23, 2025, January 23, 2026, January 23, 2027 and January 23, 2028, provided the Reporting Person continues in service with the Issuer on each such date.
F2: The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.
F3: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AKCEA THERAPEUTICS, INC.
Report date October 12, 2020 · Filed October 13, 2020
Section 16 reporting ended · disclosed 2020-10-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-12 transaction · row 1
1 source rowRow 1 · 2020-10-12 · Other · Disposed 66,800 · Balance 0 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.94 · Expires 2029-12-01 | Direct | 0 |
Reported balance
After 2020-10-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-12 · Disposition to issuer · Disposed 300,000 · Balance 0 F1: This option, which provided that 25% of the shares would vest on December 2, 2020 and then in equal monthly installments over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $63,000.00, representing the difference between the exercise price of the option and the acquisition price of $18.15. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.76 · Expires 2030-03-18 | Direct | 0 |
Reported balance
After 2020-10-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-12 · Disposition to issuer · Disposed 34,200 · Balance 0 F2: This option, which provided that 1/4th of the shares would vest one year after March 19, 2020 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $184,338.00, representing the difference between the exercise price of the option and the acquisition price of $18.15. |
Filing footnotes · ownership attribution and instrument terms
F1: This option, which provided that 25% of the shares would vest on December 2, 2020 and then in equal monthly installments over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $63,000.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.
F2: This option, which provided that 1/4th of the shares would vest one year after March 19, 2020 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $184,338.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2024 Filed Jan 25, 2024 20:29 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantMarket Stock Unit · Derivative | 4,803 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-007356 · ownership.xml · derivative · entry 3 Howarth Alex G. · CIK 0001795798 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,803 Underlying: Common Stock · 4,803 shares Expires not disclosed F3 · derivative.exercise_price: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026. F3 · derivative.exercise_date: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026. F3 · derivative.expiration_date: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:29 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 7,238 | $0.00 Strike: $229.00 | $0.00 |
DisclosureSEC source: 0000950170-24-007356 · ownership.xml · derivative · entry 2 Howarth Alex G. · CIK 0001795798 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,238 Underlying: Common Stock · 7,238 shares Expires 2031-01-23 F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:29 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 4,803 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-007356 · ownership.xml · nonDerivative · entry 1 Howarth Alex G. · CIK 0001795798 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,737 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 23, 2025, January 23, 2026, January 23, 2027 and January 23, 2028, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 18:39 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Tax withholdingCommon Stock | 1,067 | $243.92 | $260,262.64 |
DisclosureSEC source: 0000950170-24-005289 · ownership.xml · nonDerivative · entry 1 Howarth Alex G. · CIK 0001795798 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,934 F1 · kind: Represents withholding of shares as payment of the Reporting Person's tax liabilities incident to the vesting of restricted stock units granted to the Reporting Person on January 16, 2023. Read SEC document |
| January 16, 2023 Filed Jan 19, 2023 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 15,001 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-002096 · doc4.xml · nonDerivative · entry 1 Howarth Alex G. · CIK 0001795798 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,001 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 01:40 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $87.09 | $0.00 |
DisclosureSEC source: 0000899243-22-007779 · doc4.xml · derivative · entry 1 Howarth Alex G. · CIK 0001795798 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2032-02-22 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (02/22/2023) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:26 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $81.95 | $0.00 |
DisclosureSEC source: 0000899243-21-042719 · doc4.xml · derivative · entry 1 Howarth Alex G. · CIK 0001795798 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2031-11-01 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (11/1/2022) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. This option was granted under our 2015 stock plan at a regularly scheduled meeting of the Compensation Committee of our Board of Directors on November 1, 2021. Read SEC document |
| May 17, 2021 Filed May 19, 2021 19:40 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $134.00 | $0.00 |
DisclosureSEC source: 0000899243-21-019909 · doc4.xml · derivative · entry 1 Howarth Alex G. · CIK 0001795798 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2031-05-17 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (05/17/2022) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| October 12, 2020 Filed Oct 13, 2020 15:58 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Disposition to issuerStock Option (right to buy) · Derivative | 34,200 | $5.39 Strike: $12.76 | $184,338.00 |
DisclosureSEC source: 0001209191-20-054615 · doc4.xml · derivative · entry 3 Howarth Alex G. · CIK 0001795798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,200 shares Expires 2030-03-18 F2 · derivative.exercise_date: This option, which provided that 1/4th of the shares would vest one year after March 19, 2020 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $184,338.00, representing the difference between the exercise price of the option and the acquisition price of $18.15. Read SEC document |
| October 12, 2020 Filed Oct 13, 2020 15:58 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | Disposition to issuerStock Option (right to buy) · Derivative | 300,000 | $0.21 Strike: $17.94 | $63,000.00 |
DisclosureSEC source: 0001209191-20-054615 · doc4.xml · derivative · entry 2 Howarth Alex G. · CIK 0001795798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2029-12-01 F1 · derivative.exercise_date: This option, which provided that 25% of the shares would vest on December 2, 2020 and then in equal monthly installments over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $63,000.00, representing the difference between the exercise price of the option and the acquisition price of $18.15. Read SEC document |
| October 12, 2020 Filed Oct 13, 2020 15:58 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | OtherCommon Stock | 66,800 | $18.15 | $1,212,420.00 |
DisclosureSEC source: 0001209191-20-054615 · doc4.xml · nonDerivative · entry 1 Howarth Alex G. · CIK 0001795798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 16:35 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantStock Option (right to buy) · Derivative | 34,200 | $0.00 Strike: $12.76 | $0.00 |
DisclosureSEC source: 0001209191-20-020647 · doc4.xml · derivative · entry 2 Howarth Alex G. · CIK 0001795798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,200 Underlying: Common Stock · 34,200 shares Expires 2030-03-18 F2 · derivative.exercise_date: The shares vest as follows: 1/4th of the shares vest one year after March 19, 2020;1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 16:35 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantCommon Stock | 16,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-020647 · doc4.xml · nonDerivative · entry 1 Howarth Alex G. · CIK 0001795798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,800 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2015 Equity Incentive Plan. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 16:08 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0001209191-19-059037 · doc4.xml · derivative · entry 2 Howarth Alex G. · CIK 0001795798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2029-12-01 F1 · derivative.exercise_date: The shares vest as follows: 25% of the shares vest on December 2, 2020 and then in equal monthly installments over the next three years. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 16:08 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-059037 · doc4.xml · nonDerivative · entry 1 Howarth Alex G. · CIK 0001795798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.